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Limited proteolysis of Cl-inhibitor was observed with human skin chymase, human cathepsin G, and bovine chymotrypsin. In each case., the inhibi- 
tor was degraded to one major product migrating slightly faster than the native inhibitor in an SDS-polyacrylamide gel. The inhibitory activity 
of Cl-inhibitor against human plasma kallikrein was not altered by the modification with chymase. Edman degradation of the proteolyzed inhibitor 
revealed two sequences in a 1:l ratio: NPNATSSSQ, the N-terminus of native Cl-inhibitor, and VEPILEVSSL. This second sequence showed 
that the Phe’“-Val% bond was hydrolyzed. Our results provide another example of the susceptibility of the N-terminal region of Cl-inhibitor to 
proteolytic leavage. 
Cl-inhibitor; Limited proteolysis; Chymotrypsin-like proteinase; N-terminal sequence 
1. INTRODUCTION 
Cl -inhibitor inhibits human plasma kallikrein [ 1,2], 
human plasmin [2], factor XIa [3], factor XIIa [3,4], 
human thrombin [2], and Cls and Clr [5,6] forming an 
SDS-stable complex that is typical for the reaction of 
proteinases with members of the serine proteinase in- 
hibitor superfamily (serpins). The reactive center of 
Cl-inhibitor and of other serpins is located near the C- 
terminal [7] in a stressed loop [S]. Proteinases not in- 
hibited by a particular serpin can cleave within that loop 
resulting in a conformational change [9] and in a loss of 
inhibitory activity [8]. In the case of Cl-inhibitor, the 
N-terminal region is also sensitive to proteolysis 
[lO,ll]. Human leukocyte elastase and snake venom 
from Bitis arietans cleave initially in the N-terminal 
region without a loss of inhibitory activity and then 
near the reactive site [l 11. The snake venom from 
Bungarus fascia&s and Crotalus atrox a-protease, on 
the other hand, cleave only at the N-terminal region 
[lo, 111. Here we investigate the interaction of 
Cl-inhibitor with human skin chymase. Although the 
inhibitor has 6 potential cleavage sites between P’2 and 
P ‘13 (Schechter and Berger notation [12]), we show in 
this paper that Cl-inhibitor was only hydrolyzed in the 
N-terminal region. Furthermore, we present evidence 
that chymotrypsin and cathepsin G reacted with the 
Cl-inhibitor in a similar way. 
[13,14]. Cathepsin G was purified according to published methods 
[15-171. Bovine chymotrypsin was purchased from Sigma and human 
plasma kallikrein was obtained from Calbiochem. Human 
Cl-inhibitor was purified according to Harrison [18]. All substrates 
for the proteinases as well as all other chemicals were purchased from 
Sigma. 
Chymase and chymotrypsin activities were determined in 0.45 M 
Tris-HCI, pH 8.0, containing 1.8 M NaCl and 9% dimethylsulfoxide. 
The concentration of the substrate Sue-Ala-Ala-Pro-Phe-pNA was 
1 mM. Human plasma kallikrein activity was measured in 0.1 M Tris- 
HCl buffer, pH 8.3, containing 0.005% Triton X-100. The concentra- 
tion of the substrate Bz-Pro-Phe-Arg-pNA was 0.15 mM. All assays 
were performed in 1 ml cuvettes at room temperature. 
The concentration of chymotrypsin was determined with the active 
site titrant methylumbelliferyl p-trimethylammonium cinnamate 
chloride [19,20] on a fluorometer that was calibrated with a trypsin 
solution using methylumbelliferyl p-guanidinobenzoate [20]. The 
concentration of a freshly made trypsin solution was determined with 
nitrophenyl p-guanidinobenzoate [21]. Trypsin and chymotrypsin 
were used to titrate a lima bean trypsin inhibitor solution, which in 
turn was used to titrate human skin chymase. The concentration of 
cathepsin G was determined using its k&KM [22], the human plasma 
kallikrein concentration was calculated by using the weight of the 
lyophilized enzyme (1 U = l/15 mg according to the manufacturer) 
and a molecular mass of 98 kDa [23], and the Cl-inhibitor concentra- 
tion was estimated using A% = 3.6 [18]. SDS-PAGE (10% acryl- 
amide, 0.37% N ‘,N’-methylene-bis-acrylamide) was performed ac- 
cording to Laemmli [24] using a Bio-Rad Mini-Protean II dual slab 
cell. N-Terminal sequence analyses were performed at the protein 
chemistry facility at the Wistar Institute in Philadelphia. 
3. RESULTS AND DISCUSSION 
2. MATERIALS AND METHODS 
3.1. Interaction of Cl-inhibitor with human skin 
chymase 
Human skin chymase was isolated from mast cells as described 
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Cl-inhibitor was incubated with human skin chymase 
for 1 h at different inhibitor/enzyme ratios (mol/mol) 
ranging from I/E = 17 to I/E = 560 and the reaction 
was then analyzed on an SDS-polyacrylamide gel. A 
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complete conversion of the Cl-inhibitor (96 kDa) to a 
lower molecular mass (80 kDa) appeared (fig.1). The 
lowest amount of chymase able to convert more than 
90% of Cl-inhibitor was observed at a molar I/E ratio 
of 170 (fig.1, lane 4). Lowering the amount of enzyme 
to a ratio of I/E = 560 (fig. 1, lane 5), 40% of the pro- 
teolyzed Cl-inhibitor was still obtained. The limited 
proteolysis of the inhibitor could be prevented when 
chymase was preincubated either with phenylmethyl- 
sulfonylfluoride or with chymostatin (not shown). 
3.2. Interaction of Cl-inhibitor with other chymo- 
trypsin-like proteinases 
To see whether the limited proteolysis of the 
Cl-inhibitor is a common feature of chymotrypsin-like 
enzymes, we incubated the inhibitor with human 
cathepsin G and bovine chymotrypsin. Both proteinases 
were able to proteolyze Cl-inhibitor and the same SDS- 
polyacrylamide gel band pattern as with chymase was 
obtained (fig.2, lanes l-5). For these two proteinases, 
limited proteolysis was completed in 1 h only at a molar 
I/E ratio of 17 (fig.2, lanes 2 and 4). With a lesser 
amount of enzyme (I/E = 70) about 50% of the in- 
hibitor was proteolyzed in this time (fig.2, lanes 3 and 
5). A plausible reason for the slower proteolysis of 
Cl -inhibitor by human cathepsin G and bovine chymo- 
trypsin was the presence of cui-antichymotrypsin, which 
is a better inhibitor for cathepsin G and chymotrypsin 
than for chymase [25]. al-Antichymotrypsin was a very 
small impurity in our Cl-inhibitor preparation. It can 
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Fig. 1. 10% SDS-polyacrylamide electrophoresis under reduced condi- 
tions of Cl-inhibitor incubated for 1 h with chymase in 50 mM Tris- 
buffer, containing 0.5 M NaCl, pH 8.0, at different molar I/E ratios: 
no enzyme (lane 1), I/E = 17 (lane 2), I/E = 70 (lane 3), l/E = 170 (lane 
4), and I/E= 560 (lane 5). The reaction was stopped with 
phenylmethylsulfonylfluoride. Each lane contained 7 cg inhibitor. 
Molecular mass standards: phosphorylase b (98 kDa), bovine serum 
albumin (66 kDa), ovalbumin (43 kDa), and carbonic anhydrase (30 
kDa). A trace of degraded Cl-inhibitor was already present in the 
starting material. p-nitroanilline = 8800 M - ’ cm - ‘. 
Fig.3. Human plasma kallikrein inhibition by native (0) and pro- 
teolyzed (0) Cl-inhibitor. y-axis = residual kallikrein activity in mu; 
x-axis= inhibitor concentration. 100~1 human plasma kallikrein (1 U 
reconstituted in 5 ml 0.1 Tris-HCl buffer, pH 8.3, containing 0.005% 
Triton X-100) and Cl-inhibitor were preincubated for 30 min at room 
temperature. 9OOyl buffer were added and the activity was measured 
with Bz-Pro-Phe-Arg-pNA as substrate. The kallikrein concentration 
in the assay was 13.6 nM and the measured activity was 5 mU (6 for 
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Fig.2. Incubation of Cl-inhibitor with cathepsin Cl (lanes 2 and 3) and 
chymotrypsin (lanes 4 and 5). The experimental conditions were the 
same as in fig.]. Inhibitor/enzyme ratios: no enzyme (lane 1), 
I/E = 17 (lane 2 and 4) and I/E = 70 (lanes 3 and 5). 
be seen as a weak band on the SDS-polyacrylamide gels 
(molecular mass 68 kDa) and was also detected by 
Western blot analysis and by chymotrypsin inhibition in 
an activity assay (data not shown). 
3.3. Characterization of the product of limited proteo- 
lysis of Cl-inhibitor 
The product of the reaction of Cl-inhibitor with 
human skin chymase was characterized by its inhibition 
of human plasma kallikrein and by amino terminal se- 
quence analysis. Cl-inhibitor incubated with human 
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chymase for up to 20 h at room temperature did not 
change the kallikrein inhibition compared to the control 
experiment without enzyme (fig.3), indicating a 
cleavage away from the reactive center. N-Terminal se- 
quence analysis was consistent with the above observa- 
tion and confirmed that Cl-inhibitor was not cleaved 
near the reactive center. Ten Edman degradation cycles 
were performed for the native and for the proteolyzed 
inhibitor. Cl-inhibitor not treated with chymase gave 
the native sequence NPNATSSSSQ, whereas the 
limited proteolyzed inhibitor revealed in a 1: 1 ratio a 
second sequence VEPILEVSSL. Based on the publish- 
ed Cl-inhibitor sequence [8] the starting valine of that 
second sequence could be assigned to Val-34. The 
amino acid in position 33 is a Phe and cleavage of the 
Phe-33-Val-34 bond in Cl-inhibitor by human skin 
chymase is consistent with specificity of the enzyme 
P41. 
Our results with Cl-inhibitor and results reported by 
other groups [ 10,l I] show that the N-terminal region of 
Cl-inhibitor is susceptible to limited proteolysis and 
that the first 40 amino acid residues are not involved in 
the inhibitory activity. Other examples of N-terminal 
regions of proteinase inhibitors that are unimportant 
for inhibitory activity come from studies of 
oryzacystatin from rice [26], the inter-cu-trypsin in- 
hibitor from human serum [27,28], and the ovomucoid 
third domains, which often differ in the length of the 
‘connecting peptide fragment’ [29]. 
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